A novel clinical trial based on research from Cleveland Clinic’s Lerner Research Institute targets triple-negative breast cancer.

An estrogen receptor known as ERα plays a critical role in more than 70% of breast cancers.

The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Overall survival increased by 30% among women with aggressive breast cancer who began statin use post-diagnosis.

This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.

PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.

The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.